← Back to Search

ATR Kinase Inhibitor

Berzosertib + Radiation for Brain Metastases from Lung Cancer

Phase 1
Waitlist Available
Led By Pranshu Mohindra
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of M6620 (VX-970, berzosertib) in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
Group 2 patients should have archived or fresh tumor tissue available from the non-craniotomy site and will have fresh tumor tissue available from the planned craniotomy
Must not have
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib).
Patients with known diagnoses that are associated with germline DDR defects such as Li Fraumeni syndrome and ataxia telangiectasia are excluded from the study as M6620 (VX-970, berzosertib) is a DDR inhibitor.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial is testing the side effects and best dosage of a new drug, berzosertib, when given with whole brain radiation therapy, for patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread to the brain.

Who is the study for?
Adults with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread to the brain. They must be fit for whole brain radiation therapy and not pregnant or breastfeeding. Participants need functioning kidneys, a stable blood count, and agree to use contraception. Those who've had recent chemotherapy or certain treatments are excluded.
What is being tested?
The trial is testing berzosertib combined with whole brain radiation therapy against standard care for patients with specific types of lung cancer that has spread to the brain. The goal is to find out if this combination works better than current treatments.
What are the potential side effects?
Potential side effects include typical reactions from radiation like fatigue and hair loss, as well as possible effects from berzosertib such as nausea, vomiting, diarrhea, low blood counts increasing infection risk, and liver enzyme changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I can provide tumor tissue from a surgery site other than the brain and will have fresh tissue from an upcoming brain surgery.
Select...
My bilirubin levels are within the normal range for my condition.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am allergic to medications similar to M6620.
Select...
I do not have genetic conditions like Li Fraumeni syndrome or ataxia telangiectasia.
Select...
I am not pregnant or breastfeeding.
Select...
I do not have any serious ongoing illnesses or situations that would stop me from following the study's requirements.
Select...
I do not have HIV or I am not on HIV medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With a Dose-limiting Toxicity
Secondary study objectives
Changes in Quality of Life
Incidence of Delayed Neurological Toxicity
Intracranial Progression-free Survival (icPFS)
+2 more
Other study objectives
Changes in Dynamic Susceptibility Contrast-magnetic Resonance Imaging Perfusion (Group I and II)
Mean Apparent Diffusion Coefficient in Diffusion-weighted Magnetic Resonance Imaging (Group I and II)
Pharmacokinetic Characteristics of M6620 (VX-970) (Group II)

Side effects data

From 2022 Phase 2 trial • 143 Patients • NCT01622868
43%
Fatigue
33%
Headache
30%
Alopecia
25%
Nausea
19%
Anorexia
17%
Vomiting
17%
Memory impairment
16%
Pain
11%
Blurred vision
11%
Generalized muscle weakness
11%
Dizziness
11%
Dyspnea
11%
Peripheral sensory neuropathy
10%
Back pain
10%
Muscle weakness lower limb
8%
Anemia
8%
Constipation
8%
Diarrhea
8%
Paresthesia
6%
Abdominal pain
6%
Edema limbs
6%
Gait disturbance
6%
Hyperglycemia
6%
Cognitive disturbance
6%
Nervous system disorders - Other, specify
6%
Cough
5%
Weight loss
5%
Dry mouth
5%
Dyspepsia
5%
Lymphocyte count decreased
5%
Platelet count decreased
5%
Pain in extremity
5%
Depression
5%
Insomnia
5%
Skin and subcutaneous tissue disorders - Other, specify
5%
Skin hyperpigmentation
5%
Lymphedema
5%
Ataxia
5%
Dysgeusia
3%
Eye disorders - Other, specify
3%
Alanine aminotransferase increased
3%
Hypocalcemia
3%
Hyponatremia
3%
Musculoskeletal and connective tissue disorder - Other, specify
3%
Seizure
3%
Anxiety
3%
Confusion
3%
Dry skin
3%
Erythema multiforme
3%
Pruritus
3%
Hypertension
2%
Febrile neutropenia
2%
Cardiac arrest
2%
Ear pain
2%
Colonic obstruction
2%
Fever
2%
General disorders and administration site conditions - Other, specify
2%
Endocarditis infective
2%
Lung infection
2%
Alkaline phosphatase increased
2%
Dehydration
2%
Hyperkalemia
2%
Hypoalbuminemia
2%
Muscle weakness left-sided
2%
Intracranial hemorrhage
2%
Somnolence
2%
Hypoxia
2%
Pleural effusion
2%
Respiratory failure
2%
Nail loss
2%
Hypotension
2%
Thromboembolic event
2%
Vascular disorders - Other, specify
2%
Mucositis oral
2%
Urinary tract infection
2%
Dermatitis radiation
2%
Fall
2%
Aspartate aminotransferase increased
2%
Blood bilirubin increased
2%
White blood cell decreased
2%
Myalgia
2%
Dysarthria
2%
Palmar-plantar erythrodysesthesia syndrome
2%
Rash acneiform
2%
Rash maculo-papular
100%
80%
60%
40%
20%
0%
Study treatment Arm
Radiation Therapy
Lapatinib and Radiation Therapy

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group II (VX-970, surgery, whole-brain radiation therapy)Experimental Treatment4 Interventions
Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
Group II: Group I (VX-970, whole-brain radiation therapy)Experimental Treatment3 Interventions
Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Berzosertib
2021
Completed Phase 2
~80
Therapeutic Conventional Surgery
2005
Completed Phase 3
~9870
Whole-Brain Radiotherapy
2012
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,842 Previous Clinical Trials
41,002,985 Total Patients Enrolled
Pranshu MohindraPrincipal InvestigatorMayo Clinic Cancer Center LAO
1 Previous Clinical Trials
11 Total Patients Enrolled

Media Library

Berzosertib (M6620 [VX-970]) (ATR Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02589522 — Phase 1
Brain Metastasis Research Study Groups: Group I (VX-970, whole-brain radiation therapy), Group II (VX-970, surgery, whole-brain radiation therapy)
Brain Metastasis Clinical Trial 2023: Berzosertib (M6620 [VX-970]) Highlights & Side Effects. Trial Name: NCT02589522 — Phase 1
Berzosertib (M6620 [VX-970]) (ATR Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02589522 — Phase 1
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top